KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the...

Full description

Bibliographic Details
Main Authors: Andrea Casadei Gardini, Laura Capelli, Paola Ulivi, Massimo Giannini, Eva Freier, Stefano Tamberi, Emanuela Scarpi, Alassandro Passardi, Wainer Zoli, Angela Ragazzini, Dino Amadori, Giovanni Luca Frassineti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3958420?pdf=render

Internet

http://europepmc.org/articles/PMC3958420?pdf=render

Similar Items